TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10575171
Drug: Intramuscular preexposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular preexposure vaccination
Study: 10575171
Drug: Intradermal preexposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal preexposure vaccination (0.1 mL dose)
Study: 8793607
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pantoprazole and 100 mg diclofenac
Study: 1928632
Drug: Diazepam (DZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (DZ; 4‐28 mg)
Study: 1928632
Drug: Subjective drug
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjective drug effects
Study: 7047258
Drug: Carbamazepine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (600 mg daily)
Study: 23821759
Drug: Bevacizumab added
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab added to oxaliplatin-based standard adjuvant chemotherapy regimen
Study: 23821759
Drug: Standard adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjuvant chemotherapy regimen without bevacizumab
Study: 18829069
Drug: Contraceptive patch
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive patch (20 microg ethinylestradiol + 150 microg norelgestromin daily)
Study: 18829069
Drug: Vaginal ring
Normalized name: NuvaRing Vaginal Ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ring (15 microg ethinylestradiol + 120 microg etonogestrel daily)
Study: 18829069
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (30 microg ethinylestradiol + 150 microg levonorgestrel daily)
Study: 14712334
Drug: Flumazenil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (2 mg bolus injection)
Study: 11549528
Drug: Oral prednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone, 20 mg/d for 2 weeks
Study: 9802142
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg/d + Warfarin
Study: 9802142
Drug: Aspirin 160
Normalized name: aspirin 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 160 mg/d (2 h after intake)
Study: 9802142
Drug: Aspirin (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (14 patients identified as secondary aspirin non-responders)
Study: 9802142
Drug: Aspirin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (2 patients identified as primary aspirin non-responders)
Study: 26775599
Drug: Clinical pharmacist
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacist intervention focusing on medication compliance, smoking cessation, exercise, inhaler use, and follow-up.
Study: 22641932
Drug: Direct contact
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct contact person-to-person prayer intervention (six weekly 1-hour sessions)
Study: 20394720
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant human interferon alpha-2b nasal spray
Study: 11719835
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg single infusion)
Study: 9386675
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine administered at 3 days of age (n = 25)
Study: 9386675
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine administered at 1 month of age (n = 25)
Study: 7898093
Drug: Beta-blockers and
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers and centrally acting drugs
Study: 16757759
Drug: rhBMP-2 (1.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBMP-2 (1.50 mg/mL)
Study: 15251269
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous alcohol infusion
Study: 7828202
Drug: Treated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated group (29 patients) - splint therapy, physical therapy, counseling, NSAID medications
Study: 3352467
Drug: A mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: A mixture containing a fixed proportion of seven essential amino acids (L‐isoleucine 11.5%, L‐leucine 18.0%, L‐lysine 13.1%, L‐methionine 18.0%, L‐phenylalanine 18.0%, L‐threonine 8.2%, L‐valine 13.1%)
Study: 28777195
Drug: Adjustment for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustment for Sequential Organ Failure Assessment score
Study: 22211209
Drug: Enhanced mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced mental health intervention (family-based cognitive-behavioral therapy session + care linkage telephone contacts)
Study: 19147485
Drug: Pharmacological cardioversion
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological cardioversion with anti-arrhythmic drugs for 4 weeks
Study: 19147485
Drug: MMP-2 >767.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMP-2 >767.0 ng/mL
Study: 11403809
Drug: Antibiotics (clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (clarithromycin 500 mg and amoxicillin 1000 mg twice daily) for 10 days
Study: 9137510
Drug: Vinorelbine (VNB)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (VNB) weekly IV bolus of 30 mg/m (14 patients)
Study: 9137510
Drug: Vinorelbine (VNB)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (VNB) continuous infusion (CI) schedule of 8 mg IV bolus on day 1 followed by 8 mg/m2/die CI day 1 to 4, q 21 days (16 patients)
Study: 3501162
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (AP; dipyridamole 400 mg + aspirin 50 mg/day)
Study: 20461319
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD) 20‐mg capsules twice a day
Study: 17593515
Drug: steroid/Aza
Approvals — FDA: no, EMA: no, PMDA: no
Description: steroid/Aza
Study: 17593515
Drug: steroid/CsA
Approvals — FDA: no, EMA: no, PMDA: no
Description: steroid/CsA
Study: 12173200
Drug: Droperidol 0.625
Normalized name: droPERidol 0.625 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.625 mg i.v.
Study: 10441094
Drug: Lepirudin treatment
Normalized name: Lepirudin
DrugBank: Lepirudin (DB00001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lepirudin treatment (0.4 mg/kg IV bolus, followed by 0.15 mg/kg/h intravenous infusion), n=65
Study: 10441094
Drug: Lepirudin treatment
Normalized name: Lepirudin
DrugBank: Lepirudin (DB00001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lepirudin treatment in conjunction with thrombolysis (0.2 mg/kg, followed by 0.10 mg/kg/h), n=4
Study: 10441094
Drug: Lepirudin prophylaxis
Normalized name: Lepirudin
DrugBank: Lepirudin (DB00001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lepirudin prophylaxis (0.10 mg/kg/h), n=43
Study: 8588062
Drug: Serotonin reuptake
Normalized name: Selective serotonin reuptake inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin reuptake inhibitors over an 8-week period
Study: 2222943
Drug: Intravenous captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous captopril (1 to 10 mg delivered at 10 min intervals over 50 to 80 min)
Study: 2222943
Drug: Intravenous captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous captopril (incremental doses up to 40 mg)
Study: 2222943
Drug: Intravenous captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous captopril with hydrochlorothiazide
Study: 31755967
Drug: Intravitreal Ziv-Aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Ziv-Aflibercept 1.25 mg
Study: 31755967
Drug: Intravitreal Ziv-Aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Ziv-Aflibercept 2.5 mg
Study: 27918764
Drug: mFOLFOX6 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 plus onartuzumab (10 mg/kg)
Study: 27465372
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g fiber from SCF/d
Study: 27465372
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g fiber from SCF/d
Study: 24586534
Drug: Daily vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vaginal gel and oral tablet regimens (PrEP)
Study: 23096142
Drug: Stimulation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation therapy with drifting sinus gratings (n=8), performed 5 times a week over 4 weeks, 2×20 min sessions, combined with computer games
Study: 10398312
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate (50 to 75 mg of elemental zinc orally daily) for 3 years after 1 year observation in Gr A.
Study: 10398312
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 1 year followed by zinc supplementation (50 to 75 mg of elemental zinc orally daily) for 2 years in Gr B.
Study: 8523654
Drug: PGE1 (0.02‐0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE1 (0.02‐0.05 micrograms.kg‐1.min‐1 administered intravenously throughout the operation)
Study: 2578610
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (full supportive treatment only)
Study: 30739747
Drug: MISTIE treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MISTIE treatment (1·0 mg alteplase every 8 h for up to nine doses)
Study: 30739747
Drug: MISTIE treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MISTIE treatment
Study: 26085198
Drug: Intelligence seven
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intelligence seven needle therapy
Study: 21414953
Drug: Baclofen 20
Normalized name: baclofen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 20 mg t.i.d.
Study: 14709454
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron intravenously (high-risk group)
Study: 14709454
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with ondansetron (both groups)
Study: 2252164
Drug: High potency
Normalized name: High Potency B+C
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High potency (HP) extract (9-dose regimen)
Study: 6118758
Drug: dl‐propranolol (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl‐propranolol (640 mg/day)
Study: 6118758
Drug: d‐propranolol (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐propranolol (640 mg/day)
Study: 20652630
Drug: Two-session HIV/HCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-session HIV/HCV counseling and education (C&E) model added to treatment as usual (TAU)
Study: 20652630
Drug: One-session therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-session therapeutic alliance (TA) intervention conducted by outpatient counselors to facilitate treatment entry plus TAU
Study: 19649583
Drug: 1,5-pentanediol (PD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,5-pentanediol (PD) gel
Study: 11167372
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (200 microg, twice daily)
Study: 9771300
Drug: Continuous extradural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous extradural infusion of 0.125% bupivacaine 12.5 mg h‐1 and morphine 0.25 mg h‐1 (EXI group)
Study: 9771300
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with intravenous morphine (1 mg bolus, 5‐min lock‐out and maximum dose 20 mg 4h‐1)
Study: 2246759
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine added to metoclopramide regimen
Study: 44671
Drug: Ordinary metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary metoprolol tablets 0.1 g b.i.d.
Study: 44671
Drug: Metoprolol slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol slow-release tablets (Durules) 0.2 g once daily
Study: 44671
Drug: Metoprolol slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol slow-release tablets (Durules)
Study: 44671
Drug: Ordinary metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary metoprolol tablets
Study: 30209645
Drug: Tablet-based information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based information communication technology early intervention application
Study: 30209645
Drug: Therapy-as-usual
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy-as-usual
Study: 26242767
Drug: Insulin degludec/liraglutide
Normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin degludec/liraglutide (Xultophy®)
Study: 17227978
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with 6 cycles of gemcitabine on days 1, 8, and 15 every 4 weeks (n = 179)
Study: 15472185
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1200 mg calcium carbonate)
Study: 7889010
Drug: Intensive antileukaemic
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive antileukaemic therapy (vincristine, prednisone, daunorubicin, cyclophosphamide, Ara C, asparaginase)
Study: 3605674
Drug: Caudal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal morphine (0.5 mg/ml, 0.1 mg/kg)
Study: 3605674
Drug: Caudal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal bupivacaine (0.25%, 1 ml/kg)
Study: 3605674
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (control group)
Study: 23129544
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) ablation
Study: 23129544
Drug: Low-dose (LD)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose (LD) ablation
Study: 21959624
Drug: OxyContin (Oxycodone)
Normalized name: Oxycontin
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: OxyContin (Oxycodone) injections
Study: 12592328
Drug: HuM195 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuM195 at a dose of 12 mg/m(2)
Study: 12592328
Drug: HuM195 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuM195 at a dose of 36 mg/m(2)
Study: 12592328
Drug: HuM195 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuM195 (both doses)
Study: 10962963
Drug: Neutralised lignocaine-epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralised lignocaine-epinephrine (1%, 5 microgram/ml) with 1.0 ml sodium bicarbonate (8.4 g/l) added to 10 ml lignocaine-epinephrine
Study: 24394578
Drug: 60mg iron,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg iron, 500mg folic acid, 20,000 IU vitamin A, and 60mg vitamin C weekly for 5 weeks
Study: 24394578
Drug: 60mg iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg iron and 250mg folic acid weekly for 5 weeks
Study: 6464191
Drug: Oltipraz 1
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 1 X 25 mg/kg body weight
Study: 6464191
Drug: Oltipraz 1
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 1 X 35 mg/kg body weight
Study: 6464191
Drug: Oltipraz 2
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 2 X 20 mg/kg body weight
Study: 6464191
Drug: Praziquantel 2
Normalized name: praziquantel 23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 2 X 30 mg/kg body weight
Study: 30718072
Drug: Ramucirumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (8 mg/kg) plus cisplatin (80 mg/m2) and capecitabine (1000 mg/m2, twice daily for 14 days) every 21 days.
Study: 30718072
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus cisplatin (80 mg/m2) and capecitabine (1000 mg/m2, twice daily for 14 days) every 21 days.
Study: 30718072
Drug: Ramucirumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (8 mg/kg) plus cisplatin and capecitabine.
Study: 2645756
Drug: Benazepril 20
Normalized name: benazepril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 20 mg once daily
Study: 15775795
Drug: Chlorthalidone 12.5
Normalized name: chlorthalidone 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 12.5 mg once daily
Study: 12175274
Drug: PNCRM7 (PrevnarTM1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNCRM7 (PrevnarTM1) vaccine
Study: 2207950
Drug: Correspondence weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correspondence weight control program with weekly homework, interim weigh-ins, and participation deposits
Study: 344085
Drug: Trancopal 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trancopal 400 mg
Study: 28511688
Drug: Preconception supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preconception supplements containing Folic Acid, Iron and Folic Acid (IFA), or Multiple Micronutrients
Study: 28511688
Drug: Prenatal IFA
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal IFA supplements for daily consumption through delivery
Study: 28511688
Drug: Preconception supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preconception supplements
Study: 21804439
Drug: Manufacturers' guidelines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manufacturers' guidelines (cases rinsed with multipurpose solution and air dried)
Study: 21804439
Drug: Alternative cleaning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative cleaning regimen (cases rubbed, rinsed with solution, tissue wiped, and air-dried face down)
Study: 17178974
Drug: Nifedipine gastrointestinal
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine gastrointestinal therapeutic system (30 to 60 mg per day)
Study: 9167505
Drug: Sertindole 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole 24 mg/day
Study: 8064705
Drug: Controlled-release, 10-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release, 10-mg pessary
Study: 8064705
Drug: Low-dose gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose gel, 2.5-mg doses
Study: 2663165
Drug: Piroxicam 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 0.5% gel
Study: 2663165
Drug: Diclofenac 1.16%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 1.16% gel
Study: 31068954
Drug: COBRA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA therapy (prednisone 60 mg, methotrexate, sulfasalazine), n = 14
Study: 31068954
Drug: COBRA-light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA-light therapy (prednisone 30 mg, methotrexate), n = 21
Study: 20696480
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) for preventing depression
Study: 12324668
Drug: Daily rhDNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rhDNase
Study: 11171465
Drug: Propofol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (target dose 5 micrograms.ml‐1 in 5 min)
Study: 3467975
Drug: Citalopram 40
Normalized name: citalopram 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 40 mg (9 nights)
Study: 3467975
Drug: Amitriptyline 75
Normalized name: amitriptyline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 75 mg (9 nights)
Study: 20580541
Drug: Low-dose arachidonic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose arachidonic acid (80 mg ARA daily for 3 weeks)
Study: 17981455
Drug: Diclofenac and
Normalized name: diclofenac and antiinfectives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac and paracetamol
Study: 8740720
Drug: Vinorelbine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 30 mg/m2 followed by Taxol 120 mg/m2 (V/T sequence)
Study: 8740720
Drug: Taxol 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol 120 mg/m2 followed by Vinorelbine 30 mg/m2 (T/V sequence)
Study: 1930697
Drug: Oral B
Normalized name: bran ORAL BOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B 35 manual brush
Study: 29728394
Drug: Genetically determined
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically determined CETP concentration increase of 1 µg/mL
Study: 24473774
Drug: Standard-risk acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-risk acute lymphoblastic leukemia (SR-ALL) therapy
Study: 19946860
Drug: Depot form
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot form of pre-randomisation drug
Study: 16244022
Drug: Small-dose (SD)
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-dose (SD) bupivacaine (7.5 mg) with 5 mug of sufentanil
Study: 16244022
Drug: Large-dose (LD)
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-dose (LD) bupivacaine (12.5 mg) with 5 mug of sufentanil
Study: 12912857
Drug: Pharmacological agents
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological agents (sumatriptan, cisapride, erythromycin)
Study: 10680107
Drug: Cisatracurium 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.05 mg/kg (ED95)
Study: 10680107
Drug: Cisatracurium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.1 mg/kg (2 x ED95)